The Prescribing Clinical Network recommends the use of ocriplasmin in line with NICE TA 297, as an option for treating vitreomacular traction in adults.
Ocriplasmin should be used only by specialists and as such is considered as RED on the traffic light system.
Ocriplasmin is excluded from the National Tariff when administered for its licensed indication. It should only be administered within a hospital setting by suitably trained specialists, and will not be transferred to primary care. Providers should apply for funding using the Blueteq system.
